Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies
A Digital Publication for the Practicing Medical Specialist, Industry Executive and Investor
Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies
The funding will accelerate Earendil Labs’ AI-driven R&D platform, expand its interdisciplinary teams, and advance a growing pipeline of antibody and biologics programs, with the goal of delivering first-in-class and best-in-class therapies for patients with serious diseases.
Financing co-led by Taiho Ventures and Arkin Bio Capital with significant participation from other new and existing investors
The financing significantly strengthens the company’s capital position as it expands U.S. commercial infrastructure and advances clinical evidence generation across its endovascular catheter platform.
Investments support seniors, people with disabilities, family caregivers, and the direct care workforce statewide
Financing will accelerate the development of proprietary portable diagnostic platform, CoagCareTM, to enhance patient care for bleeding disorders & critical care medicine